As most of you (and your Medicare patients) have undoubtedly noticed, Medicare has applied a $35 per month cap on copays for insulin prescriptions ($105 for a 3-month supply) for years 2023-2025. For 2026 and beyond, copays will be capped at the lesser of $35 or 25% of the negotiated price.
Section 11406 of the Inflation Reduction Act of 2022 implemented this cap for Medicare Part D and Medicare Advantage patients effective January 1, 2023, while Section 11407 requires implementation for Medicare B covered insulin as of July 1, 2023.
Plan Sponsors have a 90-day grace period to implement these copay caps and any excess copays calculated at adjudication must be refunded by the plan.
- Specialty Pharmacy Paying the Price: $20 Million Settlement for Kickbacks and Copay Waivers - November 9, 2023
- Advances in Respiratory Syncytial Virus (RSV) Prevention - November 1, 2023
- OTC COVID-19 Test Prescribing Authority - October 20, 2023